Fig. 6

Effects of rivoceranib on tumour tissue in vivo. A The collected tumour tissues were subjected to western blot analysis for the evaluation of VEGFR2 activity and the expression levels of cyclin-D1. The intensity of the bands on the films was evaluated as the relative ratio of phosphorylated-VEGFR2 (P-VEGFR2) to the band intensity of VEGFR2 and the ratio of cyclin-D1 to the band intensity of β-actin. Cropped bands are displayed. Samples were derived from same experiment, and blots were processed in parallel. B, C TUNEL and anti-CD31 staining images of tumour sections in each group (vehicle and 75 mg/kg, 150 mg/kg, and 300 mg/kg rivoceranib-treated). TUNEL- and CD31-positive cells were counted in five random fields per group under a microscope. The data represent the mean ± standard deviation. * p < 0.05, ** p < 0.01 versus control group (vehicle group)